retatrutide weight loss clinical trials retatrutide New GLP-1 obesity drug, retatrutide, shows added benefits Retatrutide Phase 3: TRIUMPH Program

How does the dosing of GLP-1/GIP medications change with their intended disease target

Because the autonomic nervous system regulates digestive motility, POTS patients frequently swing between extremes: rapid gastric emptying (causing diarrhea and malabsorption) or delayed gastric emptying (gastroparesis, causing severe nausea and early satiety)

"Anti-ageing therapies should always be tailored, monitored, and based on thorough diagnostics

GLP-1 receptor agonists and risk of cancer in type 2 diabetes: An updated meta-analysis of randomized controlled trials

To this end, the amylin and glucagon-like peptide-1 (GLP-1) hormonal systems have been independently identified as promising targets for pharmacotherapy intervention 6,7,8,9,10,11